Pulmonary Arterial Hypertension – Pipeline Review,
H1 2012
Reference Code: GMDHC2006IDB
Publication Date: April 2012
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 GMDHC2006IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 7
List of Figures ................................................................................................................................................................................ 8
Introduction......................................................................................................................................................................................... 9
Global Markets Direct Report Coverage ........................................................................................................................................ 9
Pulmonary Arterial Hypertension Overview ...................................................................................................................................... 10
Therapeutics Development............................................................................................................................................................... 11
An Overview of Pipeline Products for Pulmonary Arterial Hypertension ...................................................................................... 11
Pulmonary Arterial Hypertension Therapeutics under Development by Companies ........................................................................ 13
Pulmonary Arterial Hypertension Therapeutics under Investigation by Universities/Institutes.......................................................... 15
Late Stage Products ......................................................................................................................................................................... 17
Comparative Analysis .................................................................................................................................................................. 17
Mid Clinical Stage Products.............................................................................................................................................................. 18
Comparative Analysis .................................................................................................................................................................. 18
Early Clinical Stage Products ........................................................................................................................................................... 19
Comparative Analysis .................................................................................................................................................................. 19
Pre-Clinical Stage Products.............................................................................................................................................................. 20
Comparative Analysis .................................................................................................................................................................. 20
Pulmonary Arterial Hypertension Therapeutics – Products under Development by Companies ...................................................... 21
Pulmonary Arterial Hypertension Therapeutics – Products under Investigation by Universities/Institutes ....................................... 22
Companies Involved in Pulmonary Arterial Hypertension Therapeutics Development ..................................................................... 23
United Therapeutics Corporation ................................................................................................................................................. 23
Mochida Pharmaceutical Co., Ltd. ............................................................................................................................................... 24
Novartis AG ................................................................................................................................................................................. 25
Actelion Ltd .................................................................................................................................................................................. 26
Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 27
Nippon Shinyaku Co., Ltd. ........................................................................................................................................................... 28
Bayer AG ..................................................................................................................................................................................... 29
NicOx SA ..................................................................................................................................................................................... 30
Arena Pharmaceuticals, Inc. ........................................................................................................................................................ 31
Proteo, Inc. .................................................................................................................................................................................. 32
Aires Pharmaceuticals, Inc. ......................................................................................................................................................... 33
Cardioxyl Pharmaceuticals, Inc. .................................................................................................................................................. 34
Asahi Kasei Pharma .................................................................................................................................................................... 35
Lacer, S.A. ................................................................................................................................................................................... 36
Ikaria Inc. ..................................................................................................................................................................................... 37
Pulmonary Arterial Hypertension – Therapeutics Assessment ......................................................................................................... 38
Assessment by Monotherapy Products ....................................................................................................................................... 38
Assessment by Combination Products ........................................................................................................................................ 39
Assessment by Route of Administration ...................................................................................................................................... 40
Assessment by Molecule Type .................................................................................................................................................... 42
Drug Profiles..................................................................................................................................................................................... 44
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 GMDHC2006IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
Aviptadil - Drug Profile ................................................................................................................................................................. 44
Product Description................................................................................................................................................................. 44
Mechanism of Action ............................................................................................................................................................... 44
R&D Progress ......................................................................................................................................................................... 44
Tasigna - Drug Profile.................................................................................................................................................................. 46
Product Description................................................................................................................................................................. 46
Mechanism of Action ............................................................................................................................................................... 46
R&D Progress ......................................................................................................................................................................... 46
BAY63-2521 - Drug Profile .......................................................................................................................................................... 48
Product Description................................................................................................................................................................. 48
Mechanism of Action ............................................................................................................................................................... 48
R&D Progress ......................................................................................................................................................................... 48
APD811 - Drug Profile ................................................................................................................................................................. 50
Product Description................................................................................................................................................................. 50
Mechanism of Action ............................................................................................................................................................... 50
R&D Progress ......................................................................................................................................................................... 50
QTI571 - Drug Profile .................................................................................................................................................................. 52
Product Description................................................................................................................................................................. 52
Mechanism of Action ............................................................................................................................................................... 52
R&D Progress ......................................................................................................................................................................... 52
Macitentan - Drug Profile ............................................................................................................................................................. 54
Product Description................................................................................................................................................................. 54
Mechanism of Action ............................................................................................................................................................... 54
R&D Progress ......................................................................................................................................................................... 54
AT-877 - Drug Profile................................................................................................................................................................... 56
Product Description................................................................................................................................................................. 56
Mechanism of Action ............................................................................................................................................................... 56
R&D Progress ......................................................................................................................................................................... 56
UT-15C SR - Drug Profile ............................................................................................................................................................ 57
Product Description................................................................................................................................................................. 57
Mechanism of Action ............................................................................................................................................................... 57
R&D Progress ......................................................................................................................................................................... 57
Beraprost Sodium - Drug Profile .................................................................................................................................................. 59
Product Description................................................................................................................................................................. 59
Mechanism of Action ............................................................................................................................................................... 59
R&D Progress ......................................................................................................................................................................... 59
Elafin - Drug Profile ..................................................................................................................................................................... 61
Product Description................................................................................................................................................................. 61
Mechanism of Action ............................................................................................................................................................... 61
R&D Progress ......................................................................................................................................................................... 61
Cell Based Gene Therapy - Drug Profile ..................................................................................................................................... 63
Product Description................................................................................................................................................................. 63
Mechanism of Action ............................................................................................................................................................... 63
R&D Progress ......................................................................................................................................................................... 63
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 GMDHC2006IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
LA-419 - Drug Profile ................................................................................................................................................................... 64
Product Description................................................................................................................................................................. 64
Mechanism of Action ............................................................................................................................................................... 64
R&D Progress ......................................................................................................................................................................... 64
MD-0701 - Drug Profile................................................................................................................................................................ 65
Product Description................................................................................................................................................................. 65
Mechanism of Action ............................................................................................................................................................... 65
R&D Progress ......................................................................................................................................................................... 65
Carvedilol - Drug Profile .............................................................................................................................................................. 66
Product Description................................................................................................................................................................. 66
Mechanism of Action ............................................................................................................................................................... 66
R&D Progress ......................................................................................................................................................................... 66
Selexipag - Drug Profile ............................................................................................................................................................... 67
Product Description................................................................................................................................................................. 67
Mechanism of Action ............................................................................................................................................................... 67
R&D Progress ......................................................................................................................................................................... 67
Milrinone - Drug Profile ................................................................................................................................................................ 69
Product Description................................................................................................................................................................. 69
Mechanism of Action ............................................................................................................................................................... 69
R&D Progress ......................................................................................................................................................................... 69
Warfarin - Drug Profile ................................................................................................................................................................. 70
Product Description................................................................................................................................................................. 70
Mechanism of Action ............................................................................................................................................................... 70
R&D Progress ......................................................................................................................................................................... 70
Vardenafil - Drug Profile .............................................................................................................................................................. 72
Product Description................................................................................................................................................................. 72
Mechanism of Action ............................................................................................................................................................... 72
R&D Progress ......................................................................................................................................................................... 72
Y-Secretase Inhibitor - Drug Profile ............................................................................................................................................. 73
Product Description................................................................................................................................................................. 73
Mechanism of Action ............................................................................................................................................................... 73
R&D Progress ......................................................................................................................................................................... 73
Dexmedetomidine - Drug Profile.................................................................................................................................................. 74
Product Description................................................................................................................................................................. 74
Mechanism of Action ............................................................................................................................................................... 74
R&D Progress ......................................................................................................................................................................... 74
Dichloroacetate - Drug Profile...................................................................................................................................................... 76
Product Description................................................................................................................................................................. 76
Mechanism of Action ............................................................................................................................................................... 76
R&D Progress .....................................................................................................